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A B S T R A C T
During the reproducibility validation for a time-of-flight (TOF) high-resolution mass spectrometry (HRMS)
method set up to detect 61 drugs of abuse commonly encountered in the toxicology laboratory, it was noticed
that, a number of compounds were not identified correctly during the between run analysis; the most difficult
compounds to identify were norpropoxyphene, morphine, norbuprenorphine, nortriptyline, EDDP and tramadol.
In subsequent patient comparison studies, screening a panel of 338 analytes, the TOF-HRMS method correctly
identified 211 analytes over two runs, but did not identify 127. A total of 11 false positive results were identified
by manual review of the data to be the result of confirmation ion signal-to-noise ratio(s) < 3, although one false
positive that was difficult to resolve (i.e., identification of maprotiline as amitriptyline) was due to similar
fragment ions and retention times. The TOF-HRMS method showed reasonable agreement with LC–MS/MS re-
sults, but there were a number of discrepant results. Additionally, the TOF-HRMS did detect five compounds
missed by the LC–MS/MS methods. This extensive validation effort highlights the difficulty of analysis for certain
compounds that are likely to require additional follow up prior to reporting a positive result, especially at low
and high concentrations, regardless of the type of instrumentation involved.
1. Introduction
Urine drug screening is among one of the most widely practiced
procedures in the clinical toxicology laboratory. While immunoassays
are typically used as an initial screen, confirmation is generally re-
quired to be made with liquid chromatography coupled to at least a unit
resolution (i.e., low resolution) tandem mass spectrometer (LC–MS/MS)
[1]. LC–MS/MS confirmation is made by comparing retention time (or
relative retention time) and ion ratios between one or more pairs of
precursor and product ion(s) detected in multiple reaction monitoring
(MRM) mode [2]. A primary limitation of MRM-based analytical plat-
forms is that they are restricted to a fixed panel of targeted analytes and
are unable to perform non-targeted screening. Recently, high-resolution
mass spectrometry (HRMS), including techniques such as time-of-flight
mass spectrometry (TOF-MS), has been proposed as an alternative that
would allow non-targeted drug screening [3,4]. Besides having the
ability to detect a wide range of compounds, HRMS has a much greater
specificity than immunoassays, and, therefore, does not require sec-
ondary confirmation.
In previous studies, we used a HRMS instrument to identify several
novel psychoactive substances encountered in our emergency depart-
ment [5,6], however, rigorous method validation is required to avoid
false results [7,8]. To enable non-targeted screening our laboratory and
others have utilized an “all-ions” approach for compound identification
with fragment ions created in the collision cell [7,9–11]. From previous
study we have determined that retention time, a precursor ion, and at
least one fragment ion are necessary for positive analyte identification
[7]. However, our initial study was limited in scope having only eval-
uated single spiked concentrations and patient comparisons; a more
comprehensive analysis would have included run-to-run variability,
which is an important consideration when evaluating acceptability
criteria.
The resolving power of HRMS has made it possible to measure m/z
to four decimal places, providing information that can aid in calculation
of elemental composition of unknowns. However, the variability in
exact mass measurements, especially when analyzing samples with a
complex biological matrix, has not been widely reported.
Understanding the variation in exact mass measurements that would be
expected for an assay routinely used in a clinical setting is important
since it is a critical parameter used for compound identification. Here,
https://doi.org/10.1016/j.clinms.2018.02.002
Received 11 May 2017; Received in revised form 29 January 2018; Accepted 7 February 2018
⁎ Corresponding author.
E-mail addresses: imetushi@mail.ucsd.edu (I.G. Metushi), Michael_Wakefield@waters.com (M.R. Wakefield), kara.lynch@ucsf.edu (K. Lynch), jastone@ucsd.edu (J. Stone),
rfitzgerald@ucsd.edu (R.L. Fitzgerald).
Clinical Mass Spectrometry 8 (2018) 1–7
Available online 14 February 2018
2376-9998/ © 2018 Published by Elsevier B.V. on behalf of The Association for Mass Spectrometry: Applications to the Clinical Lab (MSACL).
T
we rigorously test the reproducibility and reliability of a broad spec-
trum TOF-HRMS method by performing within run and between run
precision studies at multiple drug concentrations for 61 different drugs,
and demonstrate, by varying the exact mass tolerance of our HRMS,
how the variability in exact mass measurements caused by the analysis
matrix can affect analyte identification. Carryover and patient com-
parison studies were also conducted in order to characterize the false
positive and false negative rates using specimens submitted from var-
ious sources.
2. Materials and methods
2.1. LC conditions
LC conditions were as previously described [7]. Briefly, ultra-
performance liquid chromatography (UPLC; Waters) with a BEH C18
guard column (1.7 µm, 5mm) and a BEH C18 analytical column
(1.7 µm, 2.1×150mm) was used for separation. Flow rate was 0.4 mL/
min at a column temperature of 50 °C. Two mobile phases were used:
mobile phase A (5mmol/L ammonium formate, pH 3) and B (0.1%
formic acid in acetonitrile). A gradient was used for elution starting
with 5% B for 0.5min, increased linearly up to 50% B at 6min, and
then to 95% B at 7min where it was held for 2min, followed by re-
conditioning of the column at 5% B at 9.05min and held for 2min.
Total injection-to-injection time for one run was 14min.
2.2. TOF MS conditions
TOF MS conditions were as previously described [7]. Briefly, we
used the Xevo G2 TOF from Waters with a resolution of 20,000 (full
width at half maximum at m/z 400); capillary voltage, 0.8 kV; cone
voltage, 20 V; extraction cone, 4 V; source block temperature, 130 °C;
desolvation temperature, 550 °C; gas flow, 25 L/h; desolvation gas flow
850 L/h. Instrument calibration was performed using 5mmol/L sodium
formate in 90:10 2-propanol:water at weekly intervals (or more fre-
quently if needed). Data was acquired in profile mode through Mas-
sLynx software v4.1, SCN 869 (Waters) without real-time mass cor-
rection. The MS method consisted of 3 functions: 1) acquisition of data
over the 50–650m/z range with 6 eV collision energy (low energy); 2)
acquisition of data over a 50–650m/z range with a collision energy
ramp of 10–50 eV (high energy); 3) acquisition of lockmass data over
50–650m/z range. To process data we used UNIFI v1.7.1 (Waters),
which involved mass correction by using leucine-enkephalin with each
sample. The UNIFI database for the 61 analytes was built from the
Waters Toxicology Library and included information about molecular
formula, fragment ions and retention time for each analyte.
2.3. Method comparison studies
We used two different sample sources during validation: 1) com-
pounds were divided into six groups as previously described (10 drugs/
group with the last group having 11 drugs) [7] and spiked into drug
free urine (UTAK laboratories, CA) at three different concentrations of
100 ng/mL, 1000 ng/mL and 5000 ng/mL; 2) patient samples that were
confirmed positive using our in-house LC-MS/MS method and addi-
tional patient samples that were sent to us from the University of Ca-
lifornia, San Francisco (UCSF).
Our in-house confirmation included MRM-based LC–MS/MS
(Waters UPLC-Xevo TQ-S) methods that are routinely used to confirm
immunoassay urine drug screens. Confirmation methods from UCSF
included 5600 ABSciex QTOF, 3200 LC–MS/MS, Thermo Exactive
Orbitrap and patient prescription records [12]. Lastly, a few samples
that we were not able to confirm in-house or through UCSF were sent
out to NMS (Willow Grove, PA) or ARUP labs (Salt Lake City, Utah) for
targeted LC-MS/MS analysis.
2.4. Sample preparation
Sample preparation was as previously described [7]. Briefly, 200 µL
of urine were used for each sample. To this was added 400 µL of
deionized water, 100 µL of internal standard solution (1000 ng/mL mix
of amphetamine-D5, codeine-D3, diazepam-D5, oxazepam-D5 and
venlafaxine-D6 in methanol), and 300 µL of β-glucuronidase solution
(5000 U/mL from Helix pomatia; Sigma-Aldrich, CA) prepared in
1.0 mol/L sodium acetate buffer (pH 5). The mixture was incubated at
50 °C for 90min and centrifuged at 2010g for 10min. 20 µL of the su-
pernatant were injected for analysis.
For between run studies, samples were prepared fresh each day from
a stock solution that was stored at −20 °C for up to two months. For




Within and between run validation studies consisted of five injec-
tions of each sample within the same day and 20 injections of each
sample over 20 days, respectively. Three different concentrations of
drugs were spiked into drug free urine: 100 ng/mL, 1000 ng/mL and
5000 ng/mL. The 61 compounds were divided into six groups with the
first five groups containing 10 drugs per group and the last group
containing 11 drugs.
2.5.2. Carry-over studies
Carry-over studies were performed by spiking the 61 compounds
(divided into six groups, as described above) at 30,000 ng/mL and
analyzing them in the following order: Blank2→ Blank1→High1→
High2→ Blank1→ Blank 2→ Blank3→ Blank 1. Where “Blank” refers
to drug free urine with no drugs spiked, and “High” refers to drug free
urine spiked with 30,000 ng/mL of drug. Each “Blank” refers to a dif-
ferent preparation of drug free urine.
2.5.3. Patient comparison studies and proficiency testing samples
Using an IRB approved protocol (UCSD HRPP protocol number
90188), a total of 112 patient samples were collected from existing
clinical specimens. Patient samples were run twice. Run number one
analyzed specimens in the forward direction (e.g., sample #1→ 20)
while run number two (same sample preparation procedure) analyzed
specimens in the reverse direction (e.g., sample #20→ 1). Both runs
(i.e., run #1 and run #2) were performed on the same day for the se-
lected batch of samples; with run #2 immediately following run #1.
Proficiency testing samples were from previous challenges (i.e., year
2013–2015).
2.5.4. Sample set-up & identification criteria
For each sample batch, the following set-up was used: (1) Wash, (2)
System Suitability Test (SST), (3) Negative QC, (4) Positive QC, (5)
Samples, (6) Negative QC.
Wash: 10% methanol in LC–MS grade water. SST: all five internal
standards described above were spiked at 1000 ng/mL in 10% methanol
in LC–MS grade water. Negative QC: drug free urine (UTAK). Positive
QC: UTAK custom made in drug free urine (codeine 300 ng/mL, dox-
epin 300 ng/mL, norhydrocodone 300 ng/mL, ketamine 300 ng/mL,
meprobamate 300 ng/mL, methylphenidate 300 ng/mL, morphine-3-β-
D-glucuronide 486 ng/mL, oxazepam glucuronide 486 ng/mL, phency-
clidine 300 ng/mL, norpropoxyphene 300 ng/mL).
The criteria for a positive identification were as follows: retention
time match within 0.2 min, accurate mass of precursor ion within
5 ppm, at least one fragment with 10 ppm and detector counts ≥200.
Any compounds identified as false positive also met all of the above
criteria. UNIFI v1.7.1 was used for data processing. UNIFI involved
mass correction by use of leucine encephalin and used the “all in the RT
I.G. Metushi et al. Clinical Mass Spectrometry 8 (2018) 1–7
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window” setting to target peaks by retention time.
Criteria for batch validation were as follows: SST – 5/5 (100%)
compounds identified; Negative QC – no compounds identified; Positive




To assess method reproducibility we performed five injections for
each of the samples from the six groups (i.e., 61 total compounds) on
the same day and at three different concentrations (i.e., 100 ng/mL,
1000 ng/mL and 5000 ng/mL). When using a 5 ppm mass error
Table 1
Within run validation.
Samples were injected for a total of 5 times at three concentrations (100 ng/mL, 1000 ng/mL and 5000 ng/mL). A result of 5 indicates that the drug was identified 100% of the times (5/
5). Bold results indicate the identification criteria that were used when analyzing patient samples (tr= ± 0.2min, 5 ppm error for precursor and at least one fragment).
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tolerance, the only compounds that did not achieve a 100% identifi-
cation rate were: norpropoxyphene (missed 5/5 times at 100 ng/mL
and missed 1/5 times at 1000 ng/mL), morphine (missed 1/5 at 100 ng/
mL), amphetamine-D5 (missed 1/5 at 1000 ng/mL), amphetamine
(missed 1/5 times at 100 ng/mL), EDDP (missed 4/5 times at 100 ng/
mL) and tramadol (missed 5/5 times at 100 ng/mL), Table 1. To un-
derstand the impact of precursor mass error tolerance on these results
we tightened the mass error window to 1 and 3 ppm, or widened it to
10 ppm. Widening the mass error window to 10 ppm increased the
number of positive identifications (Table 1). Alternately, reducing the
mass tolerance error to 1 and 3 ppm increased the false negative rate
(Table 1).
3.1.2. Between run
As an additional measure of variability and reliability, the samples
analyzed above, encompassing 61 compounds at three concentration
levels, were analyzed once per day for twenty days to evaluate the
between run variability with TOF-HRMS. Using a 5 ppm mass error
tolerance, as for the within run study, norpropoxyphene, EDDP and
tramadol were frequently not detected, especially at the lowest con-
centration of 100 ng/mL (Table 2). When compared to the within run
study results, there were a larger number of analytes that were not
identified at 100% for the between run study (Table 2). We focused on
analytes that were missed more than 2/20 times in any of the three
spiked concentrations; the following compounds stood out:
Table 2
Between run validation.
Samples were injected for a total of 20 times at three concentrations over twenty days. A result of 20 indicates that the drug was identified 100% of the times (20/20). Bold results indicate
the identification criteria that were used when analyzing patient samples (tr= ± 0.2min, 5 ppm error for precursor and at least one fragment).
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norpropoxyphene, morphine, norbuprenorphine, nortriptyline, EDDP,
and tramadol. The identification rate greatly improved when the con-
centration of these analytes was increased from 100 ng/mL to 5000 ng/
mL (Table 2), as seen for norpropoxyphene, EDDP and tramadol.
However, in the case of nortriptyline, the identification rate was re-
duced at the higher concentration (from 20/20 at the concentration of
100 ng/mL and 1000 ng/mL to 16/20 at 5000 ng/mL). As for the within
run validation, we also reduced the mass error tolerance below 5 ppm
here and noted a significant increase in the number of false negative
results, while increasing the mass error tolerance increased the number
of positive identifications.
3.1.3. False positive results during within and between run validation
We did not observe any false positives during the within run vali-
dation. However, the following false positives were observed during the
between run validation studies: MDA (n=39), Norpropoxyphene
(n=3), Hydromorphone (n= 3), EDDP (n=2), Oxycodone (n= 2)
and MDMA (n=1) (data not shown).
3.1.4. Carry-over studies
Samples were spiked at 30,000 ng/mL and run as described in the
Methods section. We did not observe any carry-over to the blank
sample, which was run immediately following the two samples con-
taining the high concentration of analytes. However, analytes such as:
EDDP, MDA, Morphine, MDMA and Meprobamate were observed as
false positives during the second injection of the sample at high con-
centration (i.e., 30,000 ng/mL). None of these compounds were spiked
into the high concentration samples.
3.2. Patient comparison studies
We analyzed 112 patient specimens for the patient comparison
study. All samples were analyzed by a confirmatory method as de-
scribed in the Methods section, and in addition they were run by the
TOF-HRMS broad spectrum screen method twice. A total of 338 ana-
lytes were detected between the TOF-HRMS and the confirmatory
methods. Of these, 211 analytes were detected by both the confirmatory
methods and the TOF-HRMS method during both runs (Supplemental
Table 1), leaving 127 analytes that were discrepant between the con-
firmation method and either TOF-HRMS run #1 or run #2
(Supplemental Table 2). Fig. 1 shows the breakdown of the discrepant
findings. Of the 127 discrepant results, a total of 81 findings were
missed by the TOF run #1 and a total of 85 findings were missed by the
TOF run #2 with a total of 55 findings missed by both runs. A total of
56 results were identified between both runs of TOF-HRMS with 29
findings in run #1 and 27 findings in run #2. Ten results were false
positive by TOF run #1 versus two results for the TOF-HRMS run #2
with a grand total of 11 false positives between the two runs due to one
drug (methamphetamine) being detected in run #2 (Fig. 1), but not in
run #1 (Supplemental Table 2). Five results were identified to be true
positives by TOF-HRMS run #1 versus two for TOF run #2. An iden-
tification was determined to be “true positive” by TOF-HRMS if it met
the following conditions: the concentration of the drug was just below
the threshold of quantification by LC–MS/MS, the drug in question had
the correct metabolite pattern, the drug was consistent with the pa-
tient's prescription, the drug had the correct ion ratios, retention time
and good signal-to-noise (S/N≥ 10). For a list of specific findings refer
to Supplemental Table 2.
3.3. Proficiency testing results
A total of 89 CAP proficiency testing samples were run. UC San
Diego-TOF method missed only one compound (i.e., Tramdol) and
identified two false positives (i.e., amitriptyline and EDDP). A list of the
specific compounds can be found on Supplemental Table 3.
4. Discussion
Several reports have illustrated the usefulness of HRMS in the in-
vestigation of clinical and forensic toxicology cases [13–15]. Studies
have found good agreement between HRMS instruments and routine
LC–MS/MS, however, a limitation of these studies has been that sam-
ples were only analyzed once [7,12]. In HRMS, mass accuracy is the
main criterion used to identify analytes, because of this we evaluated
the mass error tolerance. In addition, we assessed the reliability and the
reproducibility of our TOF-HRMS method by performing multiple in-
jections for a within and between run validation study, as well as pa-
tient comparison study.
Within run analysis, where most compounds were identified at a
rate of 100% at three different concentrations (Table 1), provided a
better rate of identification for our analyte panel than between run,
where several compounds were not identified (Table 2). Two examples
where detection was made within run, but missed between run were
norbuprenorphine and MDA. Within run, at a concentration of 100 ng/
mL, norbuprenorphine and MDA were both identified 100% of the time
(Table 1), but between run they were identified 75% and 90% of the
time, respectively (Table 2). It was also observed, that the rate of
compound identification increased with increasing analyte concentra-
tion (Tables 1 and 2) for both within and between run analyses. This
was illustrated dramatically for norpropoxyphene and tramadol; nor-
propoxyphene was identified 0/20 times at a concentration of 100 ng/
mL, and 17/20 times at 5000 ng/mL (Table 2); tramadol was identified
1/20 times at 100 ng/mL and 20/20 at 1000 ng/mL and 5000 ng/mL
(Table 2).
The primary reason for failed identification was insufficient frag-
ments; retention time shifts were not found to be a factor. Occasionally,
a mass error above 5 ppm would cause a compound to go undetected.
For example, norpropoxyphene, in Group 1 of Table 2, at 1000 ng/mL it
was identified 14/20 times using the 5 ppm mass error cut-off, how-
ever, increasing the mass error to 10 ppm increased the identification to
17/20 times. As expected, reducing the mass error tolerance to 3 or
1 ppm reduced the identification frequency (Tables 1 and 2). For most
compounds, the standard deviation of the mass error varied between 1
and 3 ppm (data not shown), explaining the lower rate of identification
with a mass error tolerance of 3 or 1 ppm and the higher rate of iden-
tification with a mass error tolerance of 10 ppm.
False positive results were observed during the between run vali-
dation study, the most prominent culprit being MDA. In general, false
positives had the following criteria in common: low peak intensity (i.e.,
usually less than 500 detector counts instead of tens of thousands), and
reduced fragment presence in combination with signal-to-noise ra-
tios < 3. However, the occurrence of false positives could be elimi-
nated with analysis software that allowed specification for a minimum
signal-to-noise of the fragment ion(s), or by manual review of the data.
An unusual finding was that nortriptyline was only identified 16/20
times at a concentration of 5000 ng/mL. At this concentration a peak
was clearly present with a signal-to-noise greater than 100:1, but the
software integrated the incorrect peak. We suspect that this occurred
because the high concentration distorted the mass accuracy.
We did not observe any carry-over effects when spiking compounds
up to 30,000 ng/mL. However, on the second injection of the high
concentration of the sample, we did see some false positive results for
analytes that were not part of the target group. These false positives had
the same characteristics as discussed above (i.e., low intensity, with
fragment ion S/N < 3) and could be confirmed as false positives on
manual evaluation, except in the case of morphine. The suspected “false
positive” morphine had good signal-to-noise (i.e., > 20) along with
characteristic fragments. It was subsequently shown that morphine was
a degradation product of 6-monoacetylmorphine, a compound present
in our test specimens, so, finally, morphine was not classified as a false
positive since it was, in fact, present in the sample. The false positive
amitriptyline in the CAP sample was due to the presence of maprotiline,
I.G. Metushi et al. Clinical Mass Spectrometry 8 (2018) 1–7
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which had the same retention time and same exact mass for the pre-
cursor ion. The false positive EDDP in the CAP samples had a fragment
that was also identified by the LC-MS/MS, but confirmation failed due
to incorrect ion ratios.
For our patient comparison studies TOF-HRMS correctly identified
211 analytes (over both runs) against LC–MS/MS. A total of 127 dis-
crepant results were observed between the TOF-HRMS and the LC–MS/
MS (Fig. 1 & Supplemental Table 2). A total of 81 false negative results
were observed by TOF-HRMS during run #1 and a total of 85 false
negative results were observed during run #2. The main reasons that a
compound was missed during the patient comparison studies were as
follows (listed by frequency of occurrence): 45%, missing fragment ion;
19%, the mass accuracy was above 5 ppm; 12%, there was a missing
fragment and in addition the detector counts were below 200; 9%, the
compound was not detected by UNIFI even after removing all filters;
8%, the UNIFI software chose the wrong peak to integrate for analysis
and the remaining 7%, there was a missing fragment and a mass error
above 5 ppm. It is difficult to determine exactly why there were so
many false negative results, but it is likely due to the fact that the
LC–MS/MS methods (limit of quantification 5–100 ng/mL) were more
sensitive that the TOF-HRMS assay (limit of detection of 100–500 ng/
mL) we were evaluating. With a more sensitive TOF-HRMS instrument,
and cleaner sample preparation, it is likely that there would be fewer
false negative results.
In addition, TOF-HRMS had 10 false positive results in run #1 and
two false positive results in run #2. Overall, 29 analytes were identified
by TOF-HRMS in run #1 and another 27 different analytes were iden-
tified in run #2. However, there were a number of true positive results
identified by the TOF-HRMS that were not reported as positive by the
LC-MS/MS confirmatory method (i.e., five results in run #1 and two
results in run #2). Although LC-MS/MS identified the drug peak, the
concentrations were below the cut-off for reporting a positive.
An additional advantage of the TOF-HRMS, when used for drug
screening, is the ease by which new drugs can be added and validated,
as compared to immunoassay analyzers where the lab is required to rely
on FDA clearance for each kitted analyte or group of analytes.
Furthermore, TOF-HRMS offers improved sensitivity and selectivity
compared to traditional immunoassays. However, TOF-HRMS does
have limitations that were highlighted during this validation – speci-
fically there were some key analytes that were difficult to identify. As
shown previously [7], and in this investigation, in order to reduce false
negative results mass error tolerance must be increased to greater than
5 ppm. This leads to implementation of additional measures needed to
reduce false positives.
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